Creoptix
Latest round
- Series C
Last raised
- Sep 2019
Total raised
- $8.1M
Investors
- 2
About Creoptix
Creoptix AG, founded in 2009 in Switzerland, develops bioanalytical instruments, notably the Creoptix WAVE. The company operates from its headquarters in Zurich and has undergone a strategic pivot towards enhancing its product offerings. The founder, Kaspar Cottier, has extensive experience in the life sciences sector.Creoptix specializes in the development and provision of advanced bioanalytical instruments focused on molecular interaction analysis, primarily through its flagship product, the Creoptix WAVE. This state-of-the-art instrument employs proprietary biosensor, microfluidics, and software technologies to deliver high sensitivity and resolution, enabling researchers to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and more. The WAVE is designed to operate effectively even in complex biological environments, such as undiluted serum and plasma, making it a valuable tool for both academic research and industry applications in drug discovery.Creoptix generates revenue through direct sales of its flagship instrument, the Creoptix WAVE, along with supporting chips and software. The company engages in B2B transactions, primarily supplying products to life sciences research institutions and pharmaceutical companies. Revenue stems from the sale of hardware, with additional income derived from software licenses and support services. Partnerships with academic and industrial entities facilitate access to its products, further driving revenue through collaborative research projects.Creoptix AG is focused on developing new products to enhance its offerings, with plans to introduce advancements in molecular interaction analysis technology. The company aims to expand its reach into additional markets across Europe and North America by the end of 2023. Additionally, in January 2022, Malvern Instruments Ltd. agreed to acquire Creoptix AG, a move that is expected to bolster its operational capabilities and market access.
Who invested in Creoptix
2 investors across 1 round
See all investors in Creoptix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Sep 30, 2019
Amount
$8.1M
Investors
Questions about Creoptix
Who invested in Creoptix?
Creoptix has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Creoptix raised?
Creoptix has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Creoptix last raise money?
Creoptix's most recent round on record is a Series C, in Sep 2019.
What does Creoptix do?
Creoptix AG, founded in 2009 in Switzerland, develops bioanalytical instruments, notably the Creoptix WAVE.
Where is Creoptix headquartered?
Creoptix is headquartered in Switzerland.
Which VCs invest in companies like Creoptix?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back medical devices & equipment companies at Creoptix's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series C
Raising like Creoptix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.